JP6899975B2 - Ｍｃｌ−１阻害剤 - Google Patents
Ｍｃｌ−１阻害剤 Download PDFInfo
- Publication number
- JP6899975B2 JP6899975B2 JP2020564228A JP2020564228A JP6899975B2 JP 6899975 B2 JP6899975 B2 JP 6899975B2 JP 2020564228 A JP2020564228 A JP 2020564228A JP 2020564228 A JP2020564228 A JP 2020564228A JP 6899975 B2 JP6899975 B2 JP 6899975B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- cycloalkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C(c(cc1)cc(*(C[C@](CC2)[C@@]2[C@](C=CCCCC=O)OC)C2)c1OC[C@@]2(CCC1)C(C=C2)=C1CC2N)=O Chemical compound C*C(c(cc1)cc(*(C[C@](CC2)[C@@]2[C@](C=CCCCC=O)OC)C2)c1OC[C@@]2(CCC1)C(C=C2)=C1CC2N)=O 0.000 description 30
- GFWKXLDPGZXXPQ-UHFFFAOYSA-N COC(C(CC1)C1CN1c2cc(C(N=3)=O)ccc2OCCCCc2cc(Cl)ccc2C1)C=CCCCS=3=O Chemical compound COC(C(CC1)C1CN1c2cc(C(N=3)=O)ccc2OCCCCc2cc(Cl)ccc2C1)C=CCCCS=3=O GFWKXLDPGZXXPQ-UHFFFAOYSA-N 0.000 description 5
- WRWQOPOROZHNDA-UHFFFAOYSA-N CC1(CO)OCc2cc(C(OC)=O)c[n]2C1 Chemical compound CC1(CO)OCc2cc(C(OC)=O)c[n]2C1 WRWQOPOROZHNDA-UHFFFAOYSA-N 0.000 description 2
- ODISQUOMBAVLSL-UHFFFAOYSA-N COC(C(CC1)C1CN(C1)c2cc(C(N=3)=O)ccc2OCC1(CCCc1c2)c1ccc2Cl)C=CCCCS=3=O Chemical compound COC(C(CC1)C1CN(C1)c2cc(C(N=3)=O)ccc2OCC1(CCCc1c2)c1ccc2Cl)C=CCCCS=3=O ODISQUOMBAVLSL-UHFFFAOYSA-N 0.000 description 2
- LIGLPRXIJLCBTH-UHFFFAOYSA-N COC(C(CC1)C1CN1c2cc(C(N=3)=O)ccc2OCCCCc2cc([ClH]C)ccc2C1)C=CCCCS=3=O Chemical compound COC(C(CC1)C1CN1c2cc(C(N=3)=O)ccc2OCCCCc2cc([ClH]C)ccc2C1)C=CCCCS=3=O LIGLPRXIJLCBTH-UHFFFAOYSA-N 0.000 description 2
- FZSNMEBPEQWKRU-BRFYHDHCSA-N CC(C(C1)[C@@H]1c1ccn[n]1C)=O Chemical compound CC(C(C1)[C@@H]1c1ccn[n]1C)=O FZSNMEBPEQWKRU-BRFYHDHCSA-N 0.000 description 1
- QMLWJPWSANBMHP-UHFFFAOYSA-N CC(C(C=CC(C(CC1)C1CN(C1)c2cc(C(N=3)=O)ccc2OCCCCc2c1ccc(Cl)c2)OC)O)C(NC(c1c[n](C)nc1OC)=O)S=3=O Chemical compound CC(C(C=CC(C(CC1)C1CN(C1)c2cc(C(N=3)=O)ccc2OCCCCc2c1ccc(Cl)c2)OC)O)C(NC(c1c[n](C)nc1OC)=O)S=3=O QMLWJPWSANBMHP-UHFFFAOYSA-N 0.000 description 1
- WSUMHFNEPOYLJM-LJGSYFOKSA-N CC(C)(C)OC(N[C@H](C1)C[C@@H]1O)=O Chemical compound CC(C)(C)OC(N[C@H](C1)C[C@@H]1O)=O WSUMHFNEPOYLJM-LJGSYFOKSA-N 0.000 description 1
- VMHFXCNIPKVCBL-KYZUINATSA-N CC(C)(C)OC(N[C@H](C1)C[C@@H]1OC(N(C)C)=O)=O Chemical compound CC(C)(C)OC(N[C@H](C1)C[C@@H]1OC(N(C)C)=O)=O VMHFXCNIPKVCBL-KYZUINATSA-N 0.000 description 1
- KTQPHMZRTCUQJS-YVOMEFJGSA-N CC(C)CC(NS(CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCCc1c3)c1ccc3[ClH]C)OC)(=NC2=O)=O)=O Chemical compound CC(C)CC(NS(CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCCc1c3)c1ccc3[ClH]C)OC)(=NC2=O)=O)=O KTQPHMZRTCUQJS-YVOMEFJGSA-N 0.000 description 1
- NDAVCWMOCNERDO-HSGARQEVSA-N CC(C)[C@@H](C)C/C=C/[C@@H]([C@H]1[C@H](CN(C2)c(cc(cc3)C(N=C=O)=O)c3OC[C@@]2(CCCc2c3)c2ccc3[ClH]C)CC1)OC Chemical compound CC(C)[C@@H](C)C/C=C/[C@@H]([C@H]1[C@H](CN(C2)c(cc(cc3)C(N=C=O)=O)c3OC[C@@]2(CCCc2c3)c2ccc3[ClH]C)CC1)OC NDAVCWMOCNERDO-HSGARQEVSA-N 0.000 description 1
- UPCKLWSLNYFNAY-UHFFFAOYSA-N CC(C1)C=Cc2c1[n](C)c(C(C)=O)c2 Chemical compound CC(C1)C=Cc2c1[n](C)c(C(C)=O)c2 UPCKLWSLNYFNAY-UHFFFAOYSA-N 0.000 description 1
- HQLMCRQRMNBGOW-UHFFFAOYSA-N CC(CC=CC(C(C)C(C)CN(C1)c2cc(C(N=3)=O)ccc2OCCCCc2c1ccc(Cl)c2)O)C(C)S=3=O Chemical compound CC(CC=CC(C(C)C(C)CN(C1)c2cc(C(N=3)=O)ccc2OCCCCc2c1ccc(Cl)c2)O)C(C)S=3=O HQLMCRQRMNBGOW-UHFFFAOYSA-N 0.000 description 1
- XLRURNYPHDMEFM-UHFFFAOYSA-O CC(CC=CC(C(C)CS(NC(C(C=N)=C[NH2+]C)=O)(=NC1=O)=O)O)C(C)CN2c3cc1ccc3OCCCCc1cc(Cl)ccc1C2 Chemical compound CC(CC=CC(C(C)CS(NC(C(C=N)=C[NH2+]C)=O)(=NC1=O)=O)O)C(C)CN2c3cc1ccc3OCCCCc1cc(Cl)ccc1C2 XLRURNYPHDMEFM-UHFFFAOYSA-O 0.000 description 1
- RJCQSAKLAYSGQE-UHFFFAOYSA-N CC(CC=CC(C(CC1)C1CN(C1)c(cc(cc2)C(N=3)=O)c2OCC1(CCC1)c(cc2)c1cc2Cl)OC)C(C)S=3=O Chemical compound CC(CC=CC(C(CC1)C1CN(C1)c(cc(cc2)C(N=3)=O)c2OCC1(CCC1)c(cc2)c1cc2Cl)OC)C(C)S=3=O RJCQSAKLAYSGQE-UHFFFAOYSA-N 0.000 description 1
- OPCJCRPIEYLMJM-UHFFFAOYSA-N CC(CC=CC(C(CC1)C1CN(C1)c(cc(cc2)C(N=3)=O)c2OCC1(CCC1)c(cc2)c1cc2Cl)OC)C(NC(N(C1)CC1(COC)O)=O)S=3=O Chemical compound CC(CC=CC(C(CC1)C1CN(C1)c(cc(cc2)C(N=3)=O)c2OCC1(CCC1)c(cc2)c1cc2Cl)OC)C(NC(N(C1)CC1(COC)O)=O)S=3=O OPCJCRPIEYLMJM-UHFFFAOYSA-N 0.000 description 1
- JBFRGXUOBSZVPU-UHFFFAOYSA-N CC(CC=CC(C(CC1)C1CN(C1)c(cc(cc2)C(N=3)=O)c2OCC1(CCCc1c2)c1ccc2[ClH]C)OC)CS=3=O Chemical compound CC(CC=CC(C(CC1)C1CN(C1)c(cc(cc2)C(N=3)=O)c2OCC1(CCCc1c2)c1ccc2[ClH]C)OC)CS=3=O JBFRGXUOBSZVPU-UHFFFAOYSA-N 0.000 description 1
- JITURUNLJAKYQW-UHFFFAOYSA-N CC(CC=CC(C(CC1)C1CN(C1)c2cc(C(N=3)=O)ccc2OCCCCc2c1ccc(Cl)c2)OC)CS=3=[O]CNC(NC1CC1)=O Chemical compound CC(CC=CC(C(CC1)C1CN(C1)c2cc(C(N=3)=O)ccc2OCCCCc2c1ccc(Cl)c2)OC)CS=3=[O]CNC(NC1CC1)=O JITURUNLJAKYQW-UHFFFAOYSA-N 0.000 description 1
- IJIJBSWQABUMKO-UHFFFAOYSA-N CC(CC=CC(C(CC1)C1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc(Cl)ccc2C1)O)C(C)S=3=O Chemical compound CC(CC=CC(C(CC1)C1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc(Cl)ccc2C1)O)C(C)S=3=O IJIJBSWQABUMKO-UHFFFAOYSA-N 0.000 description 1
- FEDLWLYBXANKFF-UHFFFAOYSA-N CC(CC=CC(C(CC1)C1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc(Cl)ccc2C1)OC)CS=3=[O]NC(N(C1)CC1OC(N1CCCCC1)=O)=O Chemical compound CC(CC=CC(C(CC1)C1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc(Cl)ccc2C1)OC)CS=3=[O]NC(N(C1)CC1OC(N1CCCCC1)=O)=O FEDLWLYBXANKFF-UHFFFAOYSA-N 0.000 description 1
- ZNLSZGSTWQVSTN-UHFFFAOYSA-N CC(CC=CC(C(CC1)C1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc([ClH]C)ccc2C1)OC)CS=3=O Chemical compound CC(CC=CC(C(CC1)C1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc([ClH]C)ccc2C1)OC)CS=3=O ZNLSZGSTWQVSTN-UHFFFAOYSA-N 0.000 description 1
- GXNDUHQSYPVFCR-UHFFFAOYSA-N CC(CC=CC(C(CC1)C1CN1c2cc(C(N=3)=O)ccc2OCCCCc2cc(Cl)ccc2C1)O)C(C[O]=C(c1c[n](CC(COC)OC2)c2c1)N)S=3=O Chemical compound CC(CC=CC(C(CC1)C1CN1c2cc(C(N=3)=O)ccc2OCCCCc2cc(Cl)ccc2C1)O)C(C[O]=C(c1c[n](CC(COC)OC2)c2c1)N)S=3=O GXNDUHQSYPVFCR-UHFFFAOYSA-N 0.000 description 1
- XIJAALPIMFSWKC-UHFFFAOYSA-O CC(CC=CC(C(CC1)C1CN1c2cc(C(N=3)=[OH+])ccc2OCCCCc2cc(Cl)ccc2C1)OC)C(NC(c1c[n](C)nc1Cl)=O)S=3=O Chemical compound CC(CC=CC(C(CC1)C1CN1c2cc(C(N=3)=[OH+])ccc2OCCCCc2cc(Cl)ccc2C1)OC)C(NC(c1c[n](C)nc1Cl)=O)S=3=O XIJAALPIMFSWKC-UHFFFAOYSA-O 0.000 description 1
- DILGHECUFVVKMB-UHFFFAOYSA-N CC(CC=CCC1CCC1)CS(=NC(c1ccc2OCCCCc3cc(Cl)ccc3CNc2c1)=O)=O Chemical compound CC(CC=CCC1CCC1)CS(=NC(c1ccc2OCCCCc3cc(Cl)ccc3CNc2c1)=O)=O DILGHECUFVVKMB-UHFFFAOYSA-N 0.000 description 1
- UTHZARVOUSYBRY-UHFFFAOYSA-N CC(CC[n]1ncnc1)=[O][O]=S(CCCC=CC(C(CC1)C1CN(C1)c(cc2cc3)c3OC(CCCc3c4)C1c3ccc4[ClH]C)OC)=NC2=O Chemical compound CC(CC[n]1ncnc1)=[O][O]=S(CCCC=CC(C(CC1)C1CN(C1)c(cc2cc3)c3OC(CCCc3c4)C1c3ccc4[ClH]C)OC)=NC2=O UTHZARVOUSYBRY-UHFFFAOYSA-N 0.000 description 1
- RCUTWJXFHHZYAK-UHFFFAOYSA-N CC(CCc1c[o]nc1)=O Chemical compound CC(CCc1c[o]nc1)=O RCUTWJXFHHZYAK-UHFFFAOYSA-N 0.000 description 1
- CQKNXWMONHNKEH-UHFFFAOYSA-N CC(CO)(C1)CC1N Chemical compound CC(CO)(C1)CC1N CQKNXWMONHNKEH-UHFFFAOYSA-N 0.000 description 1
- MKNYGCWUIBQLDL-UHFFFAOYSA-N CC(CS(=NC(c1ccc2OCCCCc3cc(Cl)ccc3CN(CC(CC3)C3CC=C3)c2c1)=O)=[O]CNC(c1c[n](C)nc1OC)=O)C3OC(CCc1ccccc1)=O Chemical compound CC(CS(=NC(c1ccc2OCCCCc3cc(Cl)ccc3CN(CC(CC3)C3CC=C3)c2c1)=O)=[O]CNC(c1c[n](C)nc1OC)=O)C3OC(CCc1ccccc1)=O MKNYGCWUIBQLDL-UHFFFAOYSA-N 0.000 description 1
- KDKVPIHORQRIGE-UHFFFAOYSA-O CC(CS(NC(C(C(OC)=N)=C[NH2+]C)=O)(=NC(c(cc1)cc(N(C2)CC(CC3)C3CC=C3)c1OCC21c2ccc(C)cc2CCC1)=O)=O)C3OC(C=N)=O Chemical compound CC(CS(NC(C(C(OC)=N)=C[NH2+]C)=O)(=NC(c(cc1)cc(N(C2)CC(CC3)C3CC=C3)c1OCC21c2ccc(C)cc2CCC1)=O)=O)C3OC(C=N)=O KDKVPIHORQRIGE-UHFFFAOYSA-O 0.000 description 1
- GWGCQYMXNQDFGS-UHFFFAOYSA-N CC(NC1(CC1)C(F)(F)F)=[O][O]=S(CCCC=CC(C(CC1)C1CN1c2cc3ccc2OCCCCc2cc([Cl]=C)ccc2C1)OC)=NC3=O Chemical compound CC(NC1(CC1)C(F)(F)F)=[O][O]=S(CCCC=CC(C(CC1)C1CN1c2cc3ccc2OCCCCc2cc([Cl]=C)ccc2C1)OC)=NC3=O GWGCQYMXNQDFGS-UHFFFAOYSA-N 0.000 description 1
- NWZUFQCYQDXMKR-UHFFFAOYSA-N CC(OC(C(CC1)C1CN1c2cc(C(N=3)=O)ccc2OCCCCc2cc(Cl)ccc2C1)C=CCCCS=3=O)=O Chemical compound CC(OC(C(CC1)C1CN1c2cc(C(N=3)=O)ccc2OCCCCc2cc(Cl)ccc2C1)C=CCCCS=3=O)=O NWZUFQCYQDXMKR-UHFFFAOYSA-N 0.000 description 1
- GLUKOFBDSYZSEX-UHFFFAOYSA-O CC(OC(C1C(CN(C2)c(cc(cc3)C(N=S(CCCC=C)([NH3+])=O)=O)c3OCC(CCc3c4)C2c3ccc4Cl)CC1)C=C)=O Chemical compound CC(OC(C1C(CN(C2)c(cc(cc3)C(N=S(CCCC=C)([NH3+])=O)=O)c3OCC(CCc3c4)C2c3ccc4Cl)CC1)C=C)=O GLUKOFBDSYZSEX-UHFFFAOYSA-O 0.000 description 1
- SCPZDZOAABVEOJ-FBILRYNDSA-N CC(O[C@H]([C@H]1[C@H](CN2c3cc(C(Cl)=O)ccc3OCCCCc3cc(Cl)ccc3C2)CC1)C=C)=O Chemical compound CC(O[C@H]([C@H]1[C@H](CN2c3cc(C(Cl)=O)ccc3OCCCCc3cc(Cl)ccc3C2)CC1)C=C)=O SCPZDZOAABVEOJ-FBILRYNDSA-N 0.000 description 1
- IHMAXOUVSSUTJK-PGVJCQHQSA-N CC(O[C@H]([C@H]1[C@H](CN2c3cc(C(N=S(CCCC=C)(N)=O)=O)ccc3OCCCCc3cc(Cl)ccc3C2)CC1)C=C)=O Chemical compound CC(O[C@H]([C@H]1[C@H](CN2c3cc(C(N=S(CCCC=C)(N)=O)=O)ccc3OCCCCc3cc(Cl)ccc3C2)CC1)C=C)=O IHMAXOUVSSUTJK-PGVJCQHQSA-N 0.000 description 1
- JDEMOPODWUKBTR-YIOBJHAYSA-N CC(O[C@H]([C@H]1[C@H](CN2c3cc(C(OC(C)=O)=O)ccc3OCCCCc3cc(Cl)ccc3C2)CC1)C=C)=O Chemical compound CC(O[C@H]([C@H]1[C@H](CN2c3cc(C(OC(C)=O)=O)ccc3OCCCCc3cc(Cl)ccc3C2)CC1)C=C)=O JDEMOPODWUKBTR-YIOBJHAYSA-N 0.000 description 1
- PFVPUDUMIOVBDG-QMMMGPOBSA-N CC([C@@H](CC1)Cc2c1cn[n]2C)=O Chemical compound CC([C@@H](CC1)Cc2c1cn[n]2C)=O PFVPUDUMIOVBDG-QMMMGPOBSA-N 0.000 description 1
- MWBPDHXRRKXVPR-UHFFFAOYSA-N CC1(C)OCc2cc(C(N)=O)c[n]2C1 Chemical compound CC1(C)OCc2cc(C(N)=O)c[n]2C1 MWBPDHXRRKXVPR-UHFFFAOYSA-N 0.000 description 1
- WHOIQOVVUUUSHN-UHFFFAOYSA-N CC1(C)OCc2cc(C(OC)=O)c[n]2C1 Chemical compound CC1(C)OCc2cc(C(OC)=O)c[n]2C1 WHOIQOVVUUUSHN-UHFFFAOYSA-N 0.000 description 1
- IBPBLEOQCPGXHI-UHFFFAOYSA-N CC1(CN2CCOCC2)OCc2cc(C(N)=O)c[n]2C1 Chemical compound CC1(CN2CCOCC2)OCc2cc(C(N)=O)c[n]2C1 IBPBLEOQCPGXHI-UHFFFAOYSA-N 0.000 description 1
- JPCLQAGQQBQVJW-UHFFFAOYSA-N CC1(CN2CCOCC2)OCc2cc(C(OC)=O)c[n]2C1 Chemical compound CC1(CN2CCOCC2)OCc2cc(C(OC)=O)c[n]2C1 JPCLQAGQQBQVJW-UHFFFAOYSA-N 0.000 description 1
- VINPRKPOYXEXBJ-HNWQIWAISA-N CCC(NS(CCCC=C)(=NC(c(cc1)cc(N(C[C@H](CC2)[C@@H]2[C@H](C=C)OC(C)=O)C2)c1OC[C@@]2(CCCc1c2)c1ccc2Cl)=O)=O)=O Chemical compound CCC(NS(CCCC=C)(=NC(c(cc1)cc(N(C[C@H](CC2)[C@@H]2[C@H](C=C)OC(C)=O)C2)c1OC[C@@]2(CCCc1c2)c1ccc2Cl)=O)=O)=O VINPRKPOYXEXBJ-HNWQIWAISA-N 0.000 description 1
- YBHKHLICQQOCAF-OMFWBQBBSA-N CCC(N[S@@](CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCCc1c3)c1ccc3Cl)OCCN1CCOCC1)(=NC2=O)=O)=O Chemical compound CCC(N[S@@](CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCCc1c3)c1ccc3Cl)OCCN1CCOCC1)(=NC2=O)=O)=O YBHKHLICQQOCAF-OMFWBQBBSA-N 0.000 description 1
- ZMWGWJKIOCPFTB-WNHRTTHISA-N CCC(N[S@@](CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CC1C=C2)c(cc3cc4)c4OCCCCC1C=C2Cl)O)(=NC3=O)=O)=O Chemical compound CCC(N[S@@](CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CC1C=C2)c(cc3cc4)c4OCCCCC1C=C2Cl)O)(=NC3=O)=O)=O ZMWGWJKIOCPFTB-WNHRTTHISA-N 0.000 description 1
- SICJOQIEDVRRCK-PRNVSFRPSA-N CCC(N[S@@](CCCCC[C@@H]([C@H](CC1)[C@@H]1CN1c2cc3ccc2OCCCCc2cc(Cl)ccc2C1)OC)(=NC3=O)=O)=O Chemical compound CCC(N[S@@](CCCCC[C@@H]([C@H](CC1)[C@@H]1CN1c2cc3ccc2OCCCCc2cc(Cl)ccc2C1)OC)(=NC3=O)=O)=O SICJOQIEDVRRCK-PRNVSFRPSA-N 0.000 description 1
- SICJOQIEDVRRCK-WVXVSXNRSA-N CCC(N[S@](CCCCC[C@@H]([C@H](CC1)[C@@H]1CN1c2cc3ccc2OCCCCc2cc(Cl)ccc2C1)OC)(=NC3=O)=O)=O Chemical compound CCC(N[S@](CCCCC[C@@H]([C@H](CC1)[C@@H]1CN1c2cc3ccc2OCCCCc2cc(Cl)ccc2C1)OC)(=NC3=O)=O)=O SICJOQIEDVRRCK-WVXVSXNRSA-N 0.000 description 1
- WNHIBAQHNBJZOS-BJEBRAEGSA-N CCCC/C=C/[C@@H]([C@H](CC)CCN(C1)c2cc(C(N=C)=O)ccc2OCCCCc2c1ccc([ClH]C)c2)OC Chemical compound CCCC/C=C/[C@@H]([C@H](CC)CCN(C1)c2cc(C(N=C)=O)ccc2OCCCCc2c1ccc([ClH]C)c2)OC WNHIBAQHNBJZOS-BJEBRAEGSA-N 0.000 description 1
- BMVAMAFDWVXSIK-MVWGNQDFSA-N CCCC/C=C/[C@@H]([C@H]1[C@H](CN(C2)c(cc(cc3)C(N=C=O)=O)c3OC[C@@]2(CCCc2c3)c2ccc3[ClH]C)CC1)OC Chemical compound CCCC/C=C/[C@@H]([C@H]1[C@H](CN(C2)c(cc(cc3)C(N=C=O)=O)c3OC[C@@]2(CCCc2c3)c2ccc3[ClH]C)CC1)OC BMVAMAFDWVXSIK-MVWGNQDFSA-N 0.000 description 1
- LPWAIMOEJNOIPH-PHWUJIRASA-N CCOC(N[S@](CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCCc1c3)c1ccc3Cl)OC)(=NC2=O)=O)=O Chemical compound CCOC(N[S@](CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCCc1c3)c1ccc3Cl)OC)(=NC2=O)=O)=O LPWAIMOEJNOIPH-PHWUJIRASA-N 0.000 description 1
- NJKPXZZVZZPQLT-UHFFFAOYSA-N CCS(N)(=N[Si](C)(C)C(C)(C)C(C)C)=O Chemical compound CCS(N)(=N[Si](C)(C)C(C)(C)C(C)C)=O NJKPXZZVZZPQLT-UHFFFAOYSA-N 0.000 description 1
- CJIAOVVJHQZWPJ-SAUBVBGGSA-N CC[C@H](CC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc(Cl)ccc2C1)OC)[S@@]=3(NC(CC)=O)=O Chemical compound CC[C@H](CC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc(Cl)ccc2C1)OC)[S@@]=3(NC(CC)=O)=O CJIAOVVJHQZWPJ-SAUBVBGGSA-N 0.000 description 1
- IPVUTRFWBVWZHH-UHFFFAOYSA-N CC[n]1nccc1CCC(N)=O Chemical compound CC[n]1nccc1CCC(N)=O IPVUTRFWBVWZHH-UHFFFAOYSA-N 0.000 description 1
- NABVSZWIWFYQMG-UHFFFAOYSA-N CN(C)C(OC(C1)CC1=N)=O Chemical compound CN(C)C(OC(C1)CC1=N)=O NABVSZWIWFYQMG-UHFFFAOYSA-N 0.000 description 1
- ZXWAWTTVTTVJJY-UHFFFAOYSA-N COC(C(CC1)C1CN(C1)c(cc(cc2)C(N=3)=O)c2OCC1(CCCc1c2)c1ccc2[ClH]C)C=CCCCS=3=O Chemical compound COC(C(CC1)C1CN(C1)c(cc(cc2)C(N=3)=O)c2OCC1(CCCc1c2)c1ccc2[ClH]C)C=CCCCS=3=O ZXWAWTTVTTVJJY-UHFFFAOYSA-N 0.000 description 1
- SPIXXJOARCFKOJ-UHFFFAOYSA-N COC(C(CC1)C1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc(Cl)ccc2C1)C=CCCCS=3=[O][O]=C(C1COC1)N Chemical compound COC(C(CC1)C1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc(Cl)ccc2C1)C=CCCCS=3=[O][O]=C(C1COC1)N SPIXXJOARCFKOJ-UHFFFAOYSA-N 0.000 description 1
- CGNKVEVSQNBOEA-UHFFFAOYSA-N COC(C(CC1)C1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc(Cl)ccc2C1)C=CCCCS=3=[O][O]=C(CCC1CCCC1)N Chemical compound COC(C(CC1)C1CN1c(cc(cc2)C(N=3)=O)c2OCCCCc2cc(Cl)ccc2C1)C=CCCCS=3=[O][O]=C(CCC1CCCC1)N CGNKVEVSQNBOEA-UHFFFAOYSA-N 0.000 description 1
- YOUNMZFITBZEFQ-UHFFFAOYSA-N COC(C(CC1)C1CN1c2cc(C(N=3)=O)ccc2OCCCCC(C=C(CC2)Cl)=C2C1)C=CCCCS=3=O Chemical compound COC(C(CC1)C1CN1c2cc(C(N=3)=O)ccc2OCCCCC(C=C(CC2)Cl)=C2C1)C=CCCCS=3=O YOUNMZFITBZEFQ-UHFFFAOYSA-N 0.000 description 1
- ZXHMUBDFGKAQTO-UHFFFAOYSA-N COC(c1c[n](CCC(C2)O)c2c1)=O Chemical compound COC(c1c[n](CCC(C2)O)c2c1)=O ZXHMUBDFGKAQTO-UHFFFAOYSA-N 0.000 description 1
- HLMSUUBVYIRPJR-UHFFFAOYSA-N COC1Cc2cc(C(N)=O)c[n]2CC1 Chemical compound COC1Cc2cc(C(N)=O)c[n]2CC1 HLMSUUBVYIRPJR-UHFFFAOYSA-N 0.000 description 1
- SBZRHKUYLRTOCU-UHFFFAOYSA-N COC1Cc2cc(C(O)=O)c[n]2CC1 Chemical compound COC1Cc2cc(C(O)=O)c[n]2CC1 SBZRHKUYLRTOCU-UHFFFAOYSA-N 0.000 description 1
- SAWWGDFBTDKRKW-UHFFFAOYSA-N COC1Cc2cc(C(OC)=O)c[n]2CC1 Chemical compound COC1Cc2cc(C(OC)=O)c[n]2CC1 SAWWGDFBTDKRKW-UHFFFAOYSA-N 0.000 description 1
- QLJGOMVOYZOGHK-IZKNKHSVSA-N C[C@@H](C/C=C/C(CCc1ccc(C)cc1)[C@H](C)CS(NC(c1c[n](C)nc1OC)=O)(=NC1=O)=O)[C@@H](C)CN2c3cc1ccc3OCCCCc1cc(Cl)ccc1C2 Chemical compound C[C@@H](C/C=C/C(CCc1ccc(C)cc1)[C@H](C)CS(NC(c1c[n](C)nc1OC)=O)(=NC1=O)=O)[C@@H](C)CN2c3cc1ccc3OCCCCc1cc(Cl)ccc1C2 QLJGOMVOYZOGHK-IZKNKHSVSA-N 0.000 description 1
- FXBCFUWVOBYMLZ-XVWQUJQCSA-N C[C@@H](C/C=C/C[C@H](CC1)[C@@H]1CN(C[C@@]1(COC2=CC34)C5C=CC(Cl)=CC5CCC1)C2=CC3C4C(N1)=O)CS1(Cc1c(C[O]=C)[n](C)cc1C(N)=O)=O Chemical compound C[C@@H](C/C=C/C[C@H](CC1)[C@@H]1CN(C[C@@]1(COC2=CC34)C5C=CC(Cl)=CC5CCC1)C2=CC3C4C(N1)=O)CS1(Cc1c(C[O]=C)[n](C)cc1C(N)=O)=O FXBCFUWVOBYMLZ-XVWQUJQCSA-N 0.000 description 1
- FAXIGGZTMHPNQG-YCVJGWPDSA-N C[C@@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN1c2cc(C(N=3)=O)ccc2OCCCCc2cc(Cl)ccc2C1)OC)C[S]=3(=[NH]C(NC(C1)CN1C(OC)=O)=O)=O Chemical compound C[C@@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN1c2cc(C(N=3)=O)ccc2OCCCCc2cc(Cl)ccc2C1)OC)C[S]=3(=[NH]C(NC(C1)CN1C(OC)=O)=O)=O FAXIGGZTMHPNQG-YCVJGWPDSA-N 0.000 description 1
- IGYPLOLOKRXDKC-YRKLDDEUSA-N C[C@@H](C/C=C/[C@@H]([C@H]1[C@H](C)CC1)OC)CS(N(C(N([C@@H]1[C@@H](C)C1)N)=N)N)(=NC(c(cc1NCC2C=C3)ccc1OCCCCC2C=C3[ClH]C)=O)=O Chemical compound C[C@@H](C/C=C/[C@@H]([C@H]1[C@H](C)CC1)OC)CS(N(C(N([C@@H]1[C@@H](C)C1)N)=N)N)(=NC(c(cc1NCC2C=C3)ccc1OCCCCC2C=C3[ClH]C)=O)=O IGYPLOLOKRXDKC-YRKLDDEUSA-N 0.000 description 1
- USRCOHPHWQXSTG-GRNIBTJFSA-N C[C@@H](C/C=C/[C@@H]([C@H]1[C@H](CN2c3cc(C(N=C)=O)ccc3OCCCCc3cc(Cl)ccc3C2)CC1)OC)C(C)/[O]=C(\C)/NC(C1)[C@@H]1C(F)F Chemical compound C[C@@H](C/C=C/[C@@H]([C@H]1[C@H](CN2c3cc(C(N=C)=O)ccc3OCCCCc3cc(Cl)ccc3C2)CC1)OC)C(C)/[O]=C(\C)/NC(C1)[C@@H]1C(F)F USRCOHPHWQXSTG-GRNIBTJFSA-N 0.000 description 1
- SJNURRROGLKLAA-QFQFKQQPSA-N C[C@@H](C/C=C/[C@@H]([C@H]1[C@]2(CN3c(cc(cc4)C(N=5)=O)c4[U]CCCCc4cc([ClH]C)ccc4C3)C1C2)OC)CS=5(NC(c1c[n](C)c(Cl)c1)=O)=O Chemical compound C[C@@H](C/C=C/[C@@H]([C@H]1[C@]2(CN3c(cc(cc4)C(N=5)=O)c4[U]CCCCc4cc([ClH]C)ccc4C3)C1C2)OC)CS=5(NC(c1c[n](C)c(Cl)c1)=O)=O SJNURRROGLKLAA-QFQFKQQPSA-N 0.000 description 1
- NUGDQCCGESAINX-KACWNJMZSA-N C[C@H](C[S+](NC(c1c[n](C)nc1OC)=O)(=NC(c1ccc2OCCCCc3cc(Cl)ccc3CN(C[C@H](CC3)[C@@H]3[C@H](CC3)OC)c2c1)=O)=O)[C@H]3OC Chemical compound C[C@H](C[S+](NC(c1c[n](C)nc1OC)=O)(=NC(c1ccc2OCCCCc3cc(Cl)ccc3CN(C[C@H](CC3)[C@@H]3[C@H](CC3)OC)c2c1)=O)=O)[C@H]3OC NUGDQCCGESAINX-KACWNJMZSA-N 0.000 description 1
- ZXDQTIFGJCIMFZ-UHFFFAOYSA-N C[n]1nc(CCC(N)=O)cc1 Chemical compound C[n]1nc(CCC(N)=O)cc1 ZXDQTIFGJCIMFZ-UHFFFAOYSA-N 0.000 description 1
- YJZUQBLCWQLDEU-UHFFFAOYSA-N C[n]1ncc(C(N)=C)c1 Chemical compound C[n]1ncc(C(N)=C)c1 YJZUQBLCWQLDEU-UHFFFAOYSA-N 0.000 description 1
- SCAQIIZFVFBTQB-UHFFFAOYSA-N C[n]1nccc1CC(N)=O Chemical compound C[n]1nccc1CC(N)=O SCAQIIZFVFBTQB-UHFFFAOYSA-N 0.000 description 1
- JGXBNGMMVDMZIY-UHFFFAOYSA-N C[n]1nccc1CCC(N)=O Chemical compound C[n]1nccc1CCC(N)=O JGXBNGMMVDMZIY-UHFFFAOYSA-N 0.000 description 1
- DHNZKMWGLISFKO-LPDDFKEISA-N C[n]1nccc1CCC(N[S@@](CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN1c(cc2cc3)c3OCCCCc3cc(Cl)ccc3C1)OC)(=NC2=O)=O)=O Chemical compound C[n]1nccc1CCC(N[S@@](CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN1c(cc2cc3)c3OCCCCc3cc(Cl)ccc3C1)OC)(=NC2=O)=O)=O DHNZKMWGLISFKO-LPDDFKEISA-N 0.000 description 1
- MNFYVQWCICKQTP-BOSBUNAFSA-N C[n]1nccc1[C@@H](C1)[C@H]1C(N[S+](CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCCc1c3)c1ccc3[ClH]C)OC)(=NC2=O)=O)=O Chemical compound C[n]1nccc1[C@@H](C1)[C@H]1C(N[S+](CCC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc2cc3)c3OC[C@@]1(CCCc1c3)c1ccc3[ClH]C)OC)(=NC2=O)=O)=O MNFYVQWCICKQTP-BOSBUNAFSA-N 0.000 description 1
- QGURJTGJHLYOSY-RQJHMYQMSA-N C[n]1nccc1[C@@H](C1)[C@H]1C=O Chemical compound C[n]1nccc1[C@@H](C1)[C@H]1C=O QGURJTGJHLYOSY-RQJHMYQMSA-N 0.000 description 1
- WNYSJRZMTYUVLS-PHDIDXHHSA-N C[n]1nccc1[C@H](C1)[C@@H]1C(N)=O Chemical compound C[n]1nccc1[C@H](C1)[C@@H]1C(N)=O WNYSJRZMTYUVLS-PHDIDXHHSA-N 0.000 description 1
- LIYGIFWDAYNADQ-UHFFFAOYSA-N Cc1c[n](CCC(N)=O)nc1 Chemical compound Cc1c[n](CCC(N)=O)nc1 LIYGIFWDAYNADQ-UHFFFAOYSA-N 0.000 description 1
- MZBSJLAGBUNNLH-UHFFFAOYSA-N NC(CC(F)(F)F)=O Chemical compound NC(CC(F)(F)F)=O MZBSJLAGBUNNLH-UHFFFAOYSA-N 0.000 description 1
- VHIIRJSKNVNIAQ-UHFFFAOYSA-N NC(CC[n]1ncc2c1cccc2)=O Chemical compound NC(CC[n]1ncc2c1cccc2)=O VHIIRJSKNVNIAQ-UHFFFAOYSA-N 0.000 description 1
- LVSMFADSQWRZIF-UHFFFAOYSA-N NC(CC[n]1nncc1)=O Chemical compound NC(CC[n]1nncc1)=O LVSMFADSQWRZIF-UHFFFAOYSA-N 0.000 description 1
- FLDCAFAKYCVBLK-UHFFFAOYSA-N NC(CCc1ccncc1)=O Chemical compound NC(CCc1ccncc1)=O FLDCAFAKYCVBLK-UHFFFAOYSA-N 0.000 description 1
- ZJAUGESKXZRDFD-UHFFFAOYSA-N NC(CCc1ncccn1)=O Chemical compound NC(CCc1ncccn1)=O ZJAUGESKXZRDFD-UHFFFAOYSA-N 0.000 description 1
- HXCGVODRWMERFB-QHULZZDLSA-N N[S@@](CCC/C=C/[C@@H]([C@H]1[C@H](CN2c3cc4ccc3OCCCCc3cc(Cl)ccc3C2)C#CC1)OCCN1CCOCC1)(=NC4=O)=O Chemical compound N[S@@](CCC/C=C/[C@@H]([C@H]1[C@H](CN2c3cc4ccc3OCCCCc3cc(Cl)ccc3C2)C#CC1)OCCN1CCOCC1)(=NC4=O)=O HXCGVODRWMERFB-QHULZZDLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hematology (AREA)
- Oncology (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021037000A JP7240431B2 (ja) | 2018-05-14 | 2021-03-09 | Ｍｃｌ－１阻害剤 |
| JP2023032872A JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
| JP2025080314A JP7792036B2 (ja) | 2018-05-14 | 2025-05-13 | Ｍｃｌ－１阻害剤 |
| JP2025247816A JP2026034586A (ja) | 2018-05-14 | 2025-12-12 | Ｍｃｌ－１阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671306P | 2018-05-14 | 2018-05-14 | |
| US62/671,306 | 2018-05-14 | ||
| US201862749918P | 2018-10-24 | 2018-10-24 | |
| US62/749,918 | 2018-10-24 | ||
| PCT/US2019/032053 WO2019222112A1 (en) | 2018-05-14 | 2019-05-13 | Mcl-1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037000A Division JP7240431B2 (ja) | 2018-05-14 | 2021-03-09 | Ｍｃｌ－１阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515030A JP2021515030A (ja) | 2021-06-17 |
| JP6899975B2 true JP6899975B2 (ja) | 2021-07-07 |
Family
ID=66770559
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564228A Active JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Ｍｃｌ−１阻害剤 |
| JP2021037000A Active JP7240431B2 (ja) | 2018-05-14 | 2021-03-09 | Ｍｃｌ－１阻害剤 |
| JP2023032872A Pending JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
| JP2025080314A Active JP7792036B2 (ja) | 2018-05-14 | 2025-05-13 | Ｍｃｌ－１阻害剤 |
| JP2025247816A Pending JP2026034586A (ja) | 2018-05-14 | 2025-12-12 | Ｍｃｌ－１阻害剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037000A Active JP7240431B2 (ja) | 2018-05-14 | 2021-03-09 | Ｍｃｌ－１阻害剤 |
| JP2023032872A Pending JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
| JP2025080314A Active JP7792036B2 (ja) | 2018-05-14 | 2025-05-13 | Ｍｃｌ－１阻害剤 |
| JP2025247816A Pending JP2026034586A (ja) | 2018-05-14 | 2025-12-12 | Ｍｃｌ－１阻害剤 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10703733B2 (https=) |
| EP (2) | EP3793565B1 (https=) |
| JP (5) | JP6899975B2 (https=) |
| KR (4) | KR102551319B1 (https=) |
| CN (2) | CN117304130A (https=) |
| AU (4) | AU2019269391B2 (https=) |
| BR (1) | BR112020021648A2 (https=) |
| CA (1) | CA3099152C (https=) |
| CL (1) | CL2020002919A1 (https=) |
| CO (1) | CO2020014009A2 (https=) |
| CR (1) | CR20200544A (https=) |
| CY (1) | CY1125065T1 (https=) |
| DK (1) | DK3793565T3 (https=) |
| ES (1) | ES2907923T3 (https=) |
| HR (1) | HRP20220215T1 (https=) |
| HU (1) | HUE057852T2 (https=) |
| IL (2) | IL291430B2 (https=) |
| LT (1) | LT3793565T (https=) |
| MX (1) | MX2020012137A (https=) |
| MY (1) | MY198871A (https=) |
| PE (1) | PE20210004A1 (https=) |
| PH (1) | PH12020551881A1 (https=) |
| PL (1) | PL3793565T3 (https=) |
| PT (1) | PT3793565T (https=) |
| SG (1) | SG11202010964VA (https=) |
| SI (1) | SI3793565T1 (https=) |
| TW (3) | TWI813957B (https=) |
| UA (1) | UA125163C2 (https=) |
| WO (1) | WO2019222112A1 (https=) |
| ZA (1) | ZA202007007B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3793565B1 (en) | 2018-05-14 | 2022-01-05 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| EP3643711A1 (en) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| CN114096546A (zh) | 2019-07-09 | 2022-02-25 | 詹森药业有限公司 | 用作mcl-1抑制剂的大环螺环衍生物 |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN114787139B (zh) | 2019-11-26 | 2025-03-11 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| WO2021211922A1 (en) * | 2020-04-16 | 2021-10-21 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| AU2021288987A1 (en) * | 2020-06-10 | 2023-02-09 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of MCL-1 |
| EP4247783A1 (en) | 2020-11-19 | 2023-09-27 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
| ES3026771T3 (en) | 2020-12-17 | 2025-06-12 | Janssen Pharmaceutica Nv | Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024516641A (ja) | 2021-04-26 | 2024-04-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| JP7673255B2 (ja) * | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) * | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024544570A (ja) | 2021-11-16 | 2024-12-03 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アミノ－ブト－３－エナミド |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN119255998A (zh) * | 2022-05-04 | 2025-01-03 | 吉利德科学公司 | 特定mcl-1抑制剂的盐和多晶型物 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| CA2693310C (en) | 2007-08-02 | 2018-11-27 | Arresto Biosciences, Inc. | Lox and loxl2 inhibitors, antibodies and uses thereof |
| DK2604693T3 (en) | 2008-07-21 | 2016-05-30 | Apogenix Gmbh | Single-chain TNFSF molecules |
| US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| US8680246B2 (en) | 2010-02-04 | 2014-03-25 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (LOXL2) |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| KR101930179B1 (ko) | 2010-08-27 | 2018-12-17 | 길리아드 바이오로직스, 인크. | 매트릭스 메탈로프로테이나제 ９에 대한 항체 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| WO2013027802A1 (ja) | 2011-08-23 | 2013-02-28 | 中外製薬株式会社 | 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体 |
| GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
| JP2014528451A (ja) | 2011-10-04 | 2014-10-27 | ギリアード カリストガ エルエルシー | Ｐｉ３ｋの新規キノキサリン阻害剤 |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
| UY35044A (es) | 2012-09-24 | 2014-04-30 | Gilead Sciences Inc | ANTICUERPOS ANTI-dDr1 |
| NZ708864A (en) | 2012-12-21 | 2016-09-30 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| JP6207100B2 (ja) | 2012-12-21 | 2017-10-04 | ギリアード カリストガ エルエルシー | イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤 |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| ES2667173T3 (es) | 2013-06-14 | 2018-05-09 | Gilead Calistoga Llc | Inhibidores de fosfatidilinositol 3-quinasa |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| WO2015148854A1 (en) * | 2014-03-27 | 2015-10-01 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| CA2945320A1 (en) | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| NZ729618A (en) | 2014-09-26 | 2018-07-27 | Gilead Sciences Inc | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds |
| CA2969456A1 (en) | 2014-12-03 | 2016-06-09 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| CA2966234A1 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| BR112017024331A2 (pt) | 2015-05-15 | 2018-07-24 | Gilead Sciences, Inc. | composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto |
| JP6949728B2 (ja) | 2015-05-29 | 2021-10-13 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法 |
| US20180258149A1 (en) | 2015-09-17 | 2018-09-13 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US11306107B2 (en) * | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| ES3036998T3 (en) | 2017-08-18 | 2025-09-26 | Amgen Inc | Compounds that inhibit mcl-1 protein |
| EP3676270A1 (en) | 2017-08-29 | 2020-07-08 | Amgen Inc. | Macrocyclic compounds that inhibit mcl-1 protein |
| HRP20250272T1 (hr) | 2017-10-19 | 2025-04-25 | Teijin Pharma Limited | Derivati benzimidazola i njihova uporaba |
| US11274105B2 (en) | 2018-03-05 | 2022-03-15 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists |
| EP3793565B1 (en) | 2018-05-14 | 2022-01-05 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| JP7508375B2 (ja) | 2018-05-14 | 2024-07-01 | リアタ ファーマシューティカルズ インコーポレイテッド | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
| GEP20227443B (en) | 2018-05-15 | 2022-11-25 | H Lundbeck As | Magl inhibitors |
| KR20210038911A (ko) | 2018-07-24 | 2021-04-08 | 에피자임, 인코포레이티드 | Smarca2 길항제로서 유용한 피리딘-2-온 화합물 |
| KR20210089662A (ko) | 2018-11-09 | 2021-07-16 | 프렐루드 테라퓨틱스, 인코포레이티드 | 골수 세포 백혈병-1 (mcl-1) 단백질의 억제제로서 스피로-술폰아미드 유도체 |
| TWI745836B (zh) | 2019-01-18 | 2021-11-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑製劑的大螺環醚 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN114787139B (zh) | 2019-11-26 | 2025-03-11 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
| JP2021161114A (ja) | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| CA3181214A1 (en) | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthesis of vinylic protected alcohol intermediates |
| TWI827924B (zh) | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| AU2021288987A1 (en) | 2020-06-10 | 2023-02-09 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of MCL-1 |
| KR20230035621A (ko) | 2020-07-08 | 2023-03-14 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서 인돌 유도체를 함유하는 마크로사이클릭 에테르 |
| EP4247783A1 (en) | 2020-11-19 | 2023-09-27 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
-
2019
- 2019-05-13 EP EP19728793.1A patent/EP3793565B1/en active Active
- 2019-05-13 KR KR1020207035485A patent/KR102551319B1/ko active Active
- 2019-05-13 HU HUE19728793A patent/HUE057852T2/hu unknown
- 2019-05-13 LT LTEPPCT/US2019/032053T patent/LT3793565T/lt unknown
- 2019-05-13 AU AU2019269391A patent/AU2019269391B2/en active Active
- 2019-05-13 KR KR1020247015778A patent/KR102732008B1/ko active Active
- 2019-05-13 PE PE2020001829A patent/PE20210004A1/es unknown
- 2019-05-13 HR HRP20220215TT patent/HRP20220215T1/hr unknown
- 2019-05-13 MY MYPI2020005671A patent/MY198871A/en unknown
- 2019-05-13 UA UAA202006695A patent/UA125163C2/uk unknown
- 2019-05-13 WO PCT/US2019/032053 patent/WO2019222112A1/en not_active Ceased
- 2019-05-13 CR CR20200544A patent/CR20200544A/es unknown
- 2019-05-13 SI SI201930181T patent/SI3793565T1/sl unknown
- 2019-05-13 US US16/410,457 patent/US10703733B2/en active Active
- 2019-05-13 IL IL291430A patent/IL291430B2/en unknown
- 2019-05-13 PL PL19728793T patent/PL3793565T3/pl unknown
- 2019-05-13 DK DK19728793.1T patent/DK3793565T3/da active
- 2019-05-13 CA CA3099152A patent/CA3099152C/en active Active
- 2019-05-13 ES ES19728793T patent/ES2907923T3/es active Active
- 2019-05-13 JP JP2020564228A patent/JP6899975B2/ja active Active
- 2019-05-13 BR BR112020021648-8A patent/BR112020021648A2/pt not_active Application Discontinuation
- 2019-05-13 CN CN202310897123.9A patent/CN117304130A/zh active Pending
- 2019-05-13 KR KR1020237022152A patent/KR102666717B1/ko active Active
- 2019-05-13 SG SG11202010964VA patent/SG11202010964VA/en unknown
- 2019-05-13 KR KR1020247038029A patent/KR20240165483A/ko active Pending
- 2019-05-13 PT PT197287931T patent/PT3793565T/pt unknown
- 2019-05-13 MX MX2020012137A patent/MX2020012137A/es unknown
- 2019-05-13 CN CN201980032695.2A patent/CN112118845B/zh active Active
- 2019-05-13 EP EP21218221.6A patent/EP4029868A1/en active Pending
- 2019-05-14 TW TW110107128A patent/TWI813957B/zh active
- 2019-05-14 TW TW108116508A patent/TWI719478B/zh active
- 2019-05-14 TW TW112131732A patent/TWI844454B/zh active
-
2020
- 2020-04-23 US US16/857,021 patent/US10988451B2/en active Active
- 2020-10-27 IL IL278336A patent/IL278336B/en unknown
- 2020-11-03 PH PH12020551881A patent/PH12020551881A1/en unknown
- 2020-11-10 CO CONC2020/0014009A patent/CO2020014009A2/es unknown
- 2020-11-10 CL CL2020002919A patent/CL2020002919A1/es unknown
- 2020-11-10 ZA ZA2020/07007A patent/ZA202007007B/en unknown
-
2021
- 2021-02-09 US US17/171,201 patent/US11643400B2/en active Active
- 2021-03-09 JP JP2021037000A patent/JP7240431B2/ja active Active
- 2021-05-25 AU AU2021203373A patent/AU2021203373B2/en active Active
-
2022
- 2022-03-16 CY CY20221100208T patent/CY1125065T1/el unknown
-
2023
- 2023-03-03 JP JP2023032872A patent/JP2023060145A/ja active Pending
- 2023-03-09 US US18/181,336 patent/US12162844B2/en active Active
- 2023-11-24 AU AU2023270332A patent/AU2023270332B2/en active Active
-
2024
- 2024-10-17 US US18/918,629 patent/US20250154116A1/en active Pending
-
2025
- 2025-05-13 JP JP2025080314A patent/JP7792036B2/ja active Active
- 2025-12-12 JP JP2025247816A patent/JP2026034586A/ja active Pending
- 2025-12-24 AU AU2025287356A patent/AU2025287356A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6899975B2 (ja) | Ｍｃｌ−１阻害剤 | |
| TWI919260B (zh) | Mcl-1抑制劑 | |
| HK40078700A (en) | Mcl-1 inhibitors | |
| HK40038496B (en) | Mcl-1 inhibitors | |
| HK40104086A (zh) | Mcl-1抑制剂 | |
| HK40048157A (en) | Mcl-1 inhibitors | |
| HK40048157B (en) | Mcl-1 inhibitors | |
| EA043742B1 (ru) | Ингибиторы mcl-1 | |
| EA051482B1 (ru) | Ингибиторы mcl-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210112 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210309 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210112 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210309 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20210412 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210414 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210528 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210611 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210615 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6899975 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |